Breast Cancer Research and Treatment

, Volume 59, Issue 3, pp 271–278 | Cite as

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

  • E.-F. Solomayer
  • I.J. Diel
  • G.C. Meyberg
  • Ch. Gollan
  • G. Bastert


Although metastasis is a frequent event in breast cancer patients, insight into the clinical course, prognosis and therapy with respect to the site of the first metastases has been poor and contradictory in former investigations. Follow-up data from 648 patients with metastatic breast cancer were statistically analyzed. Patients with bone metastases at first relapse had better overall survival (median 71 vs. 48 months; p<0.001) and survival after first metastases (median 24 vs 12 months; p<0.001) than patients with visceral metastases at first relapse. Bone was the site of first metastasis in 46%, and 71% of patients with metastatic breast cancer developed bone metastases. The localization of the second metastatic site was of prognostic relevance in patients with first visceral metastases, but not in patients with first bone metastases. The presence of osseous metastases correlated significantly with estrogen and progesterone receptor positivity, tumor grading I/II and S-phase fraction <5%. The better prognosis of patients with bone metastases is not determined exclusively by hormone receptor status. The disease is significantly more stable in patients with first bone metastases than in those with first visceral metastases.

bone metastases breast cancer clinical course localization of metastases prognosis therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Galasko CSB, Doyle FH: The detection of skeletal metastases from mammary cancer. A regional comparison between radiology and scintigraphy. Clin Radiol 23: 295–297, 1972Google Scholar
  2. 2.
    Roy RR, Nathan BE, Beales JSM, Chishoim GD: 18Fluorine total-body scans in patients with carcinoma of the prostate. Br J Urol 43: 58–64, 1971Google Scholar
  3. 3.
    Drury AB, Palmer PH, Highman WJ: Carcinomatous metastases to the vertebral bodies. J Clin Pathol 17: 448–4547, 1964Google Scholar
  4. 4.
    Tofe AJ, Francis MID, Harvey WJ: Correlation of neoplasms with incidence and localization of skeletal metastases. An analysis of 1355 diphosphonate bone scans. J Nucl Med 16: 986–989, 1975Google Scholar
  5. 5.
    Johnston AD: Pathology of metastatic tumors in bone. Clin Orthop 73: 8–32, 1970Google Scholar
  6. 6.
    Galasko CSB: Skeletal metastases. Butterworths, London, Boston, Sydney, pp. 14–21, 1986Google Scholar
  7. 7.
    Nielsen OS, Munro AJ, Tannock IF: Bone metastases: Pathology and management policy. J Clin Oncol 9: 509–524, 1991Google Scholar
  8. 8.
    Yamashita K, Takafumi U, Komatsubara Y, Koyama H, Inaji H, Yomenobu K, Ono K: Breast cancer with bone only metastases. Visceral metastases-free rate in relation to anatomic distribution of bone metastases. Cancer 69: 634–637, 1991Google Scholar
  9. 9.
    Body JJ, Coleman RE, Picart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev 22: 265–287, 1996Google Scholar
  10. 10.
    Collett D: Modelling survival data in medical research. Chapman and Hall: London, 1994Google Scholar
  11. 11.
    Swenerton KD, Legha SS, Smith TL, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552–1560, 1979Google Scholar
  12. 12.
    Kamby C, Vejborg I, Daugaard S: Clinical and radiological characteristics of bone metastases in breast cancer. Cancer 60: 2524–2531, 1987Google Scholar
  13. 13.
    Patanaphan V, Salazar OM, Poussin-Rosillo H: Prognosticators in recurrent breast cancer. A 15-year experience with irradiation. Cancer 54: 228–234, 1984Google Scholar
  14. 14.
    Scheid V, Buzdar AU, Smith TL, Hortobagyi GN: Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58: 2589–2593, 1986Google Scholar
  15. 15.
    Sherry MM, Greco FA, Johnson DA, Hainsworth JD: Metastatic breast cancer confined to the skeletal system: an indolent disease. Am J Med 81: 381–386, 1986Google Scholar
  16. 16.
    Smalley RV, Scogna DM, Malmud LS: Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases. Am J Clin Oncol 5: 161–166, 1982Google Scholar
  17. 17.
    Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61–66, 1987Google Scholar
  18. 18.
    Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77: 336–340, 1998Google Scholar
  19. 19.
    Kamby C: The pattern of metastases in human breast cancer: Methodological aspects and influence of prognostic factors. Cancer Treat Rev 17: 37–61, 1990Google Scholar
  20. 20.
    Perez JE, Machiavelli M, Leone BA, Romero A, Rabinowich MG, Vallejo CT, Bianco A, Rodriquez R, Cuevas MA, Alvarez LA: Bone-only versus visceral only metastatic pattern in breast cancer: analysis of 150 patients. Am J Clin Oncol 13: 294–298, 1990Google Scholar
  21. 21.
    Blanco G, Holli K, Heikkinen M, Kallioniemi O-P, Taskinen P: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62: 142–146, 1990Google Scholar
  22. 22.
    Fey MF, Brunner KW, Sonntag RW. Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4: 237–247, 1981Google Scholar
  23. 23.
    Hietanen P, Miettinen M, Mäkinen J: Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 22: 913–919, 1986Google Scholar
  24. 24.
    Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1, 015 breast cancer patients. J Clin Oncol 5: 55–61, 1987Google Scholar
  25. 25.
    Stewart TV, King RJ, Sext SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449–461, 1981Google Scholar
  26. 26.
    Kamby C, Andersen J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K, Thorpe SM, Norgaard T, Rose C: Histological grade and steroid receptor content of primary breast cancer: Impact on prognosis and possible modes of action. Br J Cancer 58: 480–486, 1988Google Scholar
  27. 27.
    Solomayer E-F, Diel IT, Wallwiener D, Bastert G: Breast cancer with skeletal metastases at initial diagnosis. Analysis to prognosis, course and therapy. Geburtsh Frauenheilk 57: 629–636, 1997Google Scholar
  28. 28.
    Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG: Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28: 690–692, 1992Google Scholar
  29. 29.
    Diel IJ, Solomayer E-F, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan Ch, Pescherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919, 1999Google Scholar
  30. 30.
    Coleman RE: Evaluation of bone disease in breast cancer. The Breast 3: 73–78, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • E.-F. Solomayer
    • 1
  • I.J. Diel
    • 1
  • G.C. Meyberg
    • 1
  • Ch. Gollan
    • 1
  • G. Bastert
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of HeidelbergUSA

Personalised recommendations